Phase 4 N=128 Partnership for Rapid Elimination of Trachoma
Trachoma
Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=42 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Chlamydial Conjunctivitis
Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants
N/A N=500 Antenatal Chlamydia Trachomatis and Neisseria Gonorrhoeae Testing to Prevent Adverse Neonatal Consequences
Chlamydia Trachomatis Infection · Neonatal Infection · Preterm Birth
Primary: Number of Women Diagnosed With C. Trachomatis and N. Gonorrhoeae Infection at Post-delivery — 2; 23 Participants
Phase 4 N=1,452 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia
Trichiasis
Primary: Recurrent Trichiasis in Tetracycline and Azithromycin Groups — 45; 62 Participants — p=.047
Phase 3 N=567 Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities
Chlamydial Infection
Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…
N/A N=3,345 Modified Instrumentation for Surgery to Correct Trichiasis
Trachoma
Primary: Number of Eyelids With Presence of Recurrent Trichiasis — 948; 1062; 721; 612 eyelids
N/A N=200 Genital CT Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Pilot RCT
Chlamydia Trachomatis Infection
Primary: Response Rate at Recruitment — 100; 100 Participants
Phase 1 N=65 Safety and Immunogenicity of a Chlamydia Vaccine CTH522
Trachoma
Primary: Solicited Local Injection Site Reactions — 2; 8; 3; 9 Participants — p=1
Phase 3 N=495 Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin
Urogential Chlamydia Trachomatis Infection
Primary: Microbiological Cure Rate — 94.9; 94.6 percentage of participants cured
Phase 3 N=1,892 Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants
N/A N=98 Rapid Diagnostic Assay for Gonorrhea and Chlamydia
Urethritis · Cervicitis · Sexually Transmitted Infections
Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053
Phase 4 N=177 Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM
Anal Chlamydia Infection
Primary: The Proportion of Subjects With Microbiologic Cure (Negative Rectal CT NAAT Result) at Day 29 — 0.74; 1.00 proportion of participants — p=<0.001
Phase 4 N=1,347 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
Trachoma · Chlamydia Trachomatis
Primary: Infection With Chlamydia Trachomatis Diagnosed by Use of NAATs [Nucleic Acid Amplification Test] — 57; 42; 5; 3 Participants
N/A N=52 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Trachoma
Primary: The Proportion of Communities With C. Trachomatis Infection Prevalence of 1% or Below — 7; 4 community — p=>0.05
Phase 3 N=860 Phase 2B/3 Double-blinded Placebo-controlled
Chlamydia Trachomatis Infection
Primary: Urogenital CT Infection — 14; 28 Participants — p=0.0256
Phase 2 N=100 YCFM (Youth Correctional Facilities Males)
Chlamydial Infection
Primary: Proportion of Participants Experiencing Treatment Failure After Treatment With Azithromycin for Uncomplicated Chlamydia Trachomatis (CT) in Males With and Without…
Phase 3 N=606 Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)
Urethritis
Primary: mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit — 15; 8 participants
N/A N=1,585 Clinical Study of a Diagnostic Device for NG, TV and CT in Women
Chlamydial Infection · Gonococcal Infection · Trichomoniasis
Primary: The i) Percent Sensitivity and ii) Percent Specificity of Click Device for Detection of Chlamydia Trachomatis (CT) in Self-collected Vaginal Specimens as Compared to PIS…
Phase 3 N=1,365 Bacterial Vaginosis Home Screening to Prevent STDs
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Phase 4 N=3,931 Azithromycin Reduction to Reach Elimination of Trachoma
Trachoma
Primary: Ocular Chlamydia Measured in a Population-based Sample of 0-9 Year-old Children — 0; 0 Participants
N/A N=27,473 Identification of TT Cases by Community Treatment Assistants: An Assessment
Trichiasis
Primary: TT Cases Screened Positive by CTA's and Confirmed by Graders — 9; 50 Participants
N/A N=421 Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections
Upper Respiratory Tract Infections
Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants
Phase 3 N=42 Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria
Arthritis, Reactive · Reiter Disease
Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01
Phase 2 N=305 NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
Urethritis
Primary: Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea — 3; 4; 0; 4 Participants
Phase 4 N=42 Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea
Neisseria Gonorrhoeae
Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026
Phase 3 N=76 Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Pelvic Inflammatory Disease
Primary: Response Rate (Clinical Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃…
Phase 3 N=623 Trichomonas Vaginalis Repeat Infections Among HIV Negative Women
Vaginitis Trichomonal or Due to Trichomonas
Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants
Phase 4 N=614 Efficacy of Combination Therapies for Gonorrhea Treatment
Gonorrhoea
Primary: Microbiological Efficacy of Gentamicin and Azithromycin for the Treatment of Uncomplicated Gonococcal Infection — 100 percentage of participants — p=<0.05
N/A N=700 Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial
Trichiasis · Surgery
Primary: Number of Eyelids With Post-operative Trichiasis Within 12 Months — 94; 120 Eyelids — p=0.07
N/A N=120 RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis
Chronic Endometritis
Primary: The Conversion Rate of CE (From Positive to Negative) — 89.8; 12.7 Percentage of participants